RNFT2
E3 ubiquitin-protein ligase RNFT2
Also known as: FLJ14627, RNFT2_HUMAN, TMEM118
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96EX2
- Gene
- RNFT2
- Ensembl
- ENSG00000135119
- Chromosome
- 12
- Canonical length
- 444 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
Predicted to enable ubiquitin protein ligase activity. Predicted to be involved in positive regulation of ERAD pathway. Predicted to be located in membrane. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
444 residues, UniProt reviewed canonical sequence.
>Q96EX2|RNFT2
1 MWLFTVNQVL RKMQRRHSSN TDNIPPERNR SQALSSEASV DEGGVFESLK AEAASPPALF
61 SGLSGSLPTS SFPSSLVLGS SAGGGDVFIQ MPASREEGGG RGEGGAYHHR QPHHHFHHGG
121 HRGGSLLQHV GGDHRGHSEE GGDEQPGTPA PALSELKAVI CWLQKGLPFI LILLAKLCFQ
181 HKLGIAVCIG MASTFAYANS TLREQVSLKE KRSVLVILWI LAFLAGNTLY VLYTFSSQQL
241 YNSLIFLKPN LEMLDFFDLL WIVGIADFVL KYITIALKCL IVALPKIILA VKSKGKFYLV
301 IEELSQLFRS LVPIQLWYKY IMGDDSSNSY FLGGVLIVLY SLCKSFDICG RVGGVRKALK
361 LLCTSQNYGV RATGQQCTEA GDICAICQAE FREPLILLCQ HVFCEECLCL WLDRERTCPL
421 CRSVAVDTLR CWKDGATSAH FQVYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RNFT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 4
- Mean surface accessibility (rSASA)
- 0.45
- Highest tissue expression
- 10 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 10 nTPM
- cerebellum: 8.9 nTPM
- hypothalamus: 8.3 nTPM
- basal ganglia: 7.8 nTPM
- hippocampal formation: 7.6 nTPM
- amygdala: 6.6 nTPM
Single-cell type
- late spermatids: 98 nCPM
- thyrotrophs: 67 nCPM
- early spermatids: 57 nCPM
- rod photoreceptor cells: 56 nCPM
- retinal amacrine cells: 51 nCPM
- retinal bipolar cells: 50 nCPM
Immune cell
- basophil: 0.9 nTPM
- naive B-cell: 0.8 nTPM
- memory B-cell: 0.7 nTPM
- naive CD8 T-cell: 0.6 nTPM
- neutrophil: 0.6 nTPM
- plasmacytoid DC: 0.6 nTPM
Brain region
- cerebral cortex: 44 nTPM
- pons: 41 nTPM
- hippocampal formation: 38 nTPM
- basal ganglia: 36 nTPM
- medulla oblongata: 35 nTPM
- white matter: 35 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.8
- gnomAD pLI
- 0
- gnomAD missense Z
- 2.01
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RNFT2 as an antibody target. Whether an autoantibody or antibody against RNFT2 could matter depends on whether native RNFT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RNFT2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label RNFT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...